Stocks Health care CMMB
NASDAQ · Health careChemomab Therapeutics Ltd. (CMMB)
It posted a net loss of $9M. In fiscal 2025 capital spending exceeded operating cash flow by $11.1M. At December 31, 2025 it held $7.6M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 23, 2026.
What Chemomab Therapeutics Ltd. does
Chemomab Therapeutics Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CMMB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$9M | $0.02 | -$11.1M |
| 2024 | n/a | -$13.9M | $0.04 | -$15.4M |
| 2023 | n/a | -$24.2M | $0.10 | -$23.6M |
| 2022 | n/a | -$27.6M | $0.12 | -$20.4M |
| 2021 | n/a | -$12.5M | $0.06 | -$12.6M |
| 2020 | n/a | -$6M | $0.04 | -$5.3M |
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Chemomab Therapeutics Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 25, 2026
- September 9, 2026Activist stake changed SCHEDULE 13D/A
- August 19, 2026
- August 13, 2026Passive stake (5% or more) SCHEDULE 13G
- August 10, 2026Passive stake changed SCHEDULE 13G/A
- July 16, 2026Activist stake (5% or more) SCHEDULE 13D
- July 8, 2026
- June 2, 2026
- May 14, 2026
- May 6, 2026
Insider trades
What the people running Chemomab Therapeutics Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $6.5K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 28, 2026 | Cohen Neil HarrisDirector | Sold | 1,000 | $2.8K |
| August 27, 2026 | Cohen Neil HarrisDirector | Sold | 1,304 | $3.7K |
| May 29, 2026 | Mor George AdiChief Executive Officer, Director | Bought | 4,878 | $10K |
| May 29, 2026 | Mor George AdiChief Executive Officer, Director | Bought | 4,926 | $10.2K |
| May 29, 2026 | Mor George AdiChief Executive Officer, Director | Other change | 31,712 | - |
| May 29, 2026 | Mor George AdiChief Executive Officer, Director | Other change | 18,750 | - |
Who owns CMMB
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| HBM Healthcare Investments (Cayman) Ltd.13D, may seek influence | 12.5% | September 9, 2026 |
| Erik Otto13G, passive | 6.1% | November 21, 2024 |
| Touchstone Global Investments Pty Ltd13G, passive | 5.2% | August 13, 2026 |
Largest institutional holders
Insiders
2 insiders reported holding 51,750 shares in total, about $111.8K at the last price.
| Holder | Shares |
|---|---|
| Cohen Neil HarrisDirector | 33,000 |
| Mor George AdiChief Executive Officer, Director | 18,750 |
Questions about CMMB
What does Chemomab Therapeutics Ltd. do?
Chemomab Therapeutics Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CMMB.
Is Chemomab Therapeutics Ltd. profitable?
No. In fiscal 2025 it reported a net loss of $9M.
When did Chemomab Therapeutics Ltd. last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 23, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the merger registration from September 25, 2026.
Similar companies
Compare CMMB with
Follow CMMB
Get an email when Chemomab Therapeutics Ltd. files with the SEC: results, executive changes, material agreements and annual reports.
Follow CMMB: get an email when it filesWhere the numbers come from
Financial figures are the values Chemomab Therapeutics Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.